For decades, gay and bisexual men in the United States faced a lifetime ban on donating blood and plasma. That blanket prohibition no longer exists, but the current rules still restrict many men who have sex with men (MSM) based on sexual behavior and medication use. The policy has roots in the early AIDS crisis and has evolved slowly as testing technology improved, though critics argue it still lags behind the science.
How the Ban Started in the 1980s
By early 1983, evidence pointed to a bloodborne virus as the cause of AIDS, one that could spread through both sex and blood transfusions. Between 1970 and 1980, an estimated 20,000 HIV infections and 200,000 hepatitis C infections were later traced back to contaminated blood products given to patients. At the time, no reliable screening test for HIV existed, so there was no way to check donated blood before it reached a recipient.
Because HIV prevalence was substantially higher among men who had sex with men than in the general population, blood banks adopted a lifetime donation ban for all MSM in 1985. The policy made no distinction between a man in a monogamous relationship and one with many partners. It treated sexual orientation as a proxy for risk, largely because the tools to screen individual donations simply didn’t exist yet.
How Testing Technology Changed the Picture
Modern blood screening bears little resemblance to what was available in the 1980s. Every unit of donated blood and plasma in the U.S. now undergoes nucleic acid testing (NAT), which detects the genetic material of HIV itself rather than waiting for the body to produce antibodies. NAT can identify HIV infection within 10 to 33 days of exposure, dramatically shrinking the “window period” where an infected donation could slip through undetected.
This matters because the original ban was designed for an era with no testing at all. The residual risk of HIV reaching a patient through a transfusion is now extraordinarily small: roughly 0.32 to 0.35 transmissions per million red blood cell transfusions from first-time donors. When the U.S. moved from a lifetime ban to a 12-month deferral for MSM, researchers found no statistically significant increase in either HIV incidence among donors or transfusion transmission risk.
What the Current U.S. Rules Actually Say
The FDA updated its donor eligibility guidelines in 2023, replacing the old time-based deferral (which asked all MSM to abstain from sex for a set period) with an individual risk assessment. Under the current system, the screening questionnaire asks all prospective donors, regardless of gender or orientation, whether they have had a new sexual partner in the past three months or have had more than one sexual partner in that time. If you answer yes and have also had anal sex in that window, you’re deferred.
In practice, this means a gay man in a long-term, monogamous relationship can donate. But it also means that sexually active gay and bisexual men with new or multiple partners face restrictions that don’t apply in the same way to heterosexual donors with equivalent numbers of partners. The policy is formally behavior-based rather than identity-based, but it still disproportionately affects MSM because of the specific focus on anal sex as a risk factor.
Why HIV Prevention Medication Triggers a Deferral
One of the less obvious barriers involves PrEP and PEP, medications taken to prevent HIV infection. Many gay and bisexual men take daily oral PrEP as a routine precaution. The problem for donation purposes is that these drugs suppress HIV replication so effectively that they can mask an early infection, making it invisible even to NAT screening.
If you’ve taken oral PrEP or PEP, you must wait three months after your last dose before donating. For injectable PrEP, which stays active in the body much longer, the deferral period is two years from the last injection. This creates a catch-22 for many gay men: taking responsible steps to prevent HIV simultaneously disqualifies them from donating for months or years. Since PrEP use is far more common among MSM than in the general population, this rule acts as an additional, functionally targeted restriction.
How Other Countries Handle It
The U.S. isn’t alone in grappling with this issue. The UK maintained a permanent MSM deferral from 1983 until 2011, when it shifted to a 12-month waiting period since last sexual contact between men. Australia, New Zealand, and South Africa adopted similar fixed-period deferrals. The EU’s blood safety directive focuses on “sexual behaviour” that increases risk of transmissible infections rather than naming specific groups, leaving individual countries to interpret the standard differently.
Several countries have since moved further. The UK, France, and others have adopted individual risk assessments similar to the current U.S. approach, asking about recent sexual behavior rather than applying blanket deferrals to all MSM. The trend across high-income countries has been a gradual loosening, driven by accumulating evidence that modern screening catches nearly all infected donations regardless of donor demographics.
The Core Tension That Remains
The debate comes down to competing priorities. On one side, HIV prevalence among MSM in the U.S. is genuinely higher than in the general population, and blood safety regulators are inherently conservative because a single contaminated unit can harm a vulnerable patient. On the other side, current NAT screening is remarkably sensitive, the actual transfusion risk is vanishingly small, and policies that single out a group based on sexual orientation carry real social costs, including reinforcing stigma and reducing the overall donor pool.
The shift from a lifetime ban to a behavior-based questionnaire represents a significant change, but for many gay and bisexual men the practical effect is the same: routine aspects of their lives, whether having a new partner or taking PrEP, result in deferral. The policy is no longer a blanket ban on gay men donating plasma, but the restrictions still land unevenly on MSM compared to heterosexual donors with similar risk profiles.